Colorectal cancer screening - Optimizing current strategies and new directions

Nature Reviews Clinical Oncology

Volumn 10, Issue 3, 2013, Pages 130-142

  Kuipers, Ernst J ^a   Rösch, Thomas ^b   Bretthauer, Michael ^c,d  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^c UNIVERSITY OF OSLO   (Norway)

^d OSLO UNIVERSITY HOSPITAL   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; CARCINOEMBRYONIC ANTIGEN; GUAIAC; NONSTEROID ANTIINFLAMMATORY AGENT; PROSTAGLANDIN G; PROSTAGLANDIN H;

ADULT; AGED; BLOOD ANALYSIS; CANCER INCIDENCE; CANCER MORTALITY; CANCER PREVENTION; CANCER RISK; CANCER SCREENING; COLONOSCOPY; COLORECTAL CANCER; COMPUTED TOMOGRAPHIC COLONOGRAPHY; CONTROLLED STUDY; GASTROINTESTINAL ENDOSCOPY; HEALTH CARE COST; HUMAN; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MORBIDITY; OCCULT BLOOD TEST; PRIORITY JOURNAL; QUALITY CONTROL; REVIEW; SCREENING TEST; SIGMOIDOSCOPY;

COLONIC POLYPS; COLONOGRAPHY, COMPUTED TOMOGRAPHIC; COLONOSCOPY; COLORECTAL NEOPLASMS; COLORIMETRY; COST-BENEFIT ANALYSIS; EARLY DETECTION OF CANCER; FOLLOW-UP STUDIES; FORECASTING; HEMOGLOBINS; HUMANS; IMMUNOHISTOCHEMISTRY; MODELS, THEORETICAL; OCCULT BLOOD; PATIENT ACCEPTANCE OF HEALTH CARE; PRECANCEROUS CONDITIONS; PROGRAM EVALUATION; PROSPECTIVE STUDIES; QUALITY ASSURANCE, HEALTH CARE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SENSITIVITY AND SPECIFICITY; TUMOR MARKERS, BIOLOGICAL;

EID: 84874647348     PISSN: 17594774     EISSN: 17594782     Source Type: Journal    
DOI: 10.1038/nrclinonc.2013.12     Document Type: Review

References (126)

1. Ferlay, J. et al. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int. J. Cancer 127, 2893-2917 (2010).
2. Brandstedt, J. et al. Gender, anthropometric factors and risk of colorectal cancer with particular reference to tumour location and TNM stage: a cohort study. Biol. Sex Differ. 3, 23 (2012).
3. Boyle, T., Keegel, T., Bull., F., Heyworth, J. & Fritschi, L. Physical activity and risks of proximal and distal colon cancers: a systematic review and meta-analysis. J. Natl Cancer Inst. 104, 1548-1561 (2012).
4. Kharazmi, E., Fallah, M., Sundquist, K. & Hemminki, K. Familial risk of early and late onset cancer: nationwide prospective cohort study. BMJ 345, e8076 (2012).
5. Brenner, H. et al. Risk of progression of advanced adenomas to colorectal cancer by age and sex: estimates based on 840, 149 screening colonoscopies. Gut 56, 1585-1589 (2007).
6. Kuntz, K. M. et al. A systematic comparison of microsimulation models of colorectal cancer: the role of assumptions about adenoma progression. Med. Decis. Making 31, 530-539 (2011).
7. Quintero, E. et al. Colonoscopy versus fecal immunochemical testing in colorectal-cancer screening. N. Engl. J. Med. 366, 697-706 (2012).
8. Stoop, E. M. et al. Participation and yield of colonoscopy versus non-cathartic CT colonography in population-based screening for colorectal cancer: a randomised controlled trial. Lancet Oncol. 13, 55-64 (2011).
9. Oort, F. A. et al. Colonoscopy-controlled intra-individual comparisons to screen relevant neoplasia: faecal immunochemical test vs. guaiac-based faecal occult blood test. Aliment. Pharmacol. Ther. 31, 432-439 (2010).
10. Hewitson, P., Glasziou, P., Watson, E., Towler, B. & Irwig, L. Cochrane systematic review of colorectal cancer screening using the fecal occult blood test (hemoccult): an update. Am. J. Gastroenterol. 103, 1541-1549 (2008).
11. Mandel, J. S. et al. The effect of fecal occult-blood screening on the incidence of colorectal cancer. N. Engl. J. Med. 343, 1603-1607 (2000).
12. Jørgensen, O. D., Kronborg, O. & Fenger, C. A randomised study of screening for colorectal cancer using faecal occult blood testing: results after 13 years and seven biennial screening rounds. Gut 50, 29-32 (2002).
13. Kewenter, J., Brevinge, H., Engarás, B., Haglind, E. & Ährén, C. Results of screening, rescreening, and follow-up in a prospective randomized study for detection of colorectal cancer by fecal occult blood testing. Results for 68, 308 subjects. Scand. J. Gastroenterol. 29, 468-473 (1994).
14. Hardcastle, J. D. et al. Randomised controlled trial of faecal-occult-blood screening for colorectal cancer. Lancet 348, 1472-1477 (1996).
15. Faivre, J. et al. Reduction in colorectal cancer mortality by fecal occult blood screening in a French controlled study. Gastroenterology 126, 1674-1680 (2004).
16. Duffy, M. J. et al. Use of faecal markers in screening for colorectal neoplasia: a European group on tumor markers position paper. Int. J. Cancer 128, 3-11 (2011).
17. Schoenfeld, P. et al. Colonoscopic screening of average-risk women for colorectal neoplasia. N. Engl. J. Med. 352, 2061-2068 (2005).
18. Steele, R. J. et al. Interval cancers in a FOBT-based colorectal cancer population screening programme: implications for stage, gender and tumour site. Gut 61, 576-581 (2012).
19. Hol, L. et al. Screening for colorectal cancer: randomised trial comparing guaiac-based and immunochemical faecal occult blood testing and flexible sigmoidoscopy. Gut 59, 62-68 (2010).
20. van Rossum, L. G. et al. Random comparison of guaiac and immunochemical fecal occult blood tests for colorectal cancer in a screening population. Gastroenterology 135, 82-90 (2008).
21. Konrad, G. Dietary interventions for fecal occult blood test screening: systematic review of the literature. Can. Fam. Physician 56, 229-238 (2010).
22. Levi, Z. et al. Sensitivity, but not specificity, of a quantitative immunochemical fecal occult blood test for neoplasia is slightly increased by the use of low-dose aspirin, NSAIDs, and anticoagulants. Am. J. Gastroenterol. 104, 933-938 (2009).
23. Konrad, G. & Katz, A. Are medication restrictions before FOBT necessary?: practical advice based on a systematic review of the literature. Can. Fam. Physician 58, 939-948 (2009).
24. Allard, J. et al. Gastroscopy following a positive fecal occult blood test and negative colonoscopy: systematic review and guideline. Can. J. Gastroenterol. 24, 113-120 (2010).
25. Faivre, J. et al. Comparison between a guaiac and three immunochemical faecal occult blood tests in screening for colorectal cancer. Eur. J. Cancer 48, 2969-2976 (2012).
26. Chiba, H. et al. Is it worthwhile to perform capsule endoscopy for asymptomatic patients with positive immunochemical faecal occult blood test? Dig. Dis. Sci. 56, 3459-3462 (2011).
27. Levi, Z., Vilkin, A. & Niv, Y. Esophago-gastro-duodenoscopy is not indicated in patients with positive immunochemical test and nonexplanatory colonoscopy. Eur. J. Gastroenterol. Hepatol. 22, 1431-1434 (2010).
28. Cole, S. R., Young, G. P., Esterman, A., Cadd, B. & Morcom, J. A randomised trial of the impact of new faecal haemoglobin test technologies on population participation in screening for colorectal cancer. J. Med. Screen 10, 117-122 (2003).
29. Hol, L. et al. Screening for colorectal cancer: random comparison of guaiac and immunochemical faecal occult blood testing at different cut-off levels. Br. J. Cancer 100, 1103-1110 (2009).
30. de Wijkerslooth, T. R. et al. Immunochemical fecal occult blood testing is equally sensitive for proximal and distal advanced neoplasia. Am. J. Gastroenterol. 107, 1570-1578 (2012).
31. Haug, U., Hundt, S. & Brenner, H. Quantitative immunochemical fecal occult blood testing for colorectal adenoma detection: evaluation in the target population of screening and comparison with qualitative tests. Am. J. Gastroenterol. 105, 682-690 (2010).
32. Hundt, S., Haug, U. & Brenner, H. Comparative evaluation of immunochemical fecal occult blood tests for colorectal adenoma detection. Ann. Intern. Med. 150, 162-169 (2009).
33. Allison, J. E. et al. Screening for colorectal neoplasms with new fecal occult blood tests: update on performance characteristics. J. Natl Cancer Inst. 99, 1462-1470 (2007).
34. Graser, A. et al. Comparison of CT colonography, colonoscopy, sigmoidoscopy and faecal occult blood tests for the detection of advanced adenoma in an average risk population. Gut 58, 241-248 (2009).
35. Park, D. I. et al. Comparison of guaiac-based and quantitative immunochemical fecal occult blood testing in a population at average risk undergoing colorectal cancer screening. Am. J. Gastroenterol. 105, 2017-2025 (2010).
36. van Roon, A. H. et al. Diagnostic yield improves with collection of 2 samples in fecal immunochemical test screening without affecting attendance. Clin. Gastroenterol. Hepatol. 9, 333-339 (2011).
37. Levi, Z. et al. A higher detection rate for colorectal cancer and advanced adenomatous polyp for screening with immunochemical fecal occult blood test than guaiac fecal occult blood test, despite lower compliance rate. A prospective, controlled, feasibility study. Int. J. Cancer 128, 2415-2424 (2011).
38. van Roon, A. H. et al. Random comparison of repeated faecal immunochemical testing at different intervals for population-based colorectal cancer screening. Gut http://dx.doi.org/10.1136/gutjnl-2011-301583.
39. Parente, F. et al. Impact of a population-based colorectal cancer screening program on local health services demand in Italy: a 7-year survey in a northern province. Am. J. Gastroenterol. 106, 1986-1993 (2011).
40. Crotta, S. et al. High rate of advanced adenoma detection in 4 rounds of colorectal cancer screening with the fecal immunochemical test. Clin. Gastroenterol. Hepatol. 10, 633-638 (2012).
41. Denters, M. J. et al. Lower risk of advanced neoplasia among patients with a previous negative result from a fecal test for colorectal cancer. Gastroenterology 142, 497-504 (2012).
42. Chen, L. S., Yen, A. M., Chiu, S. Y., Liao, C. S. & Chen, H. H. Baseline faecal occult blood concentration as a predictor of incident colorectal neoplasia: longitudinal follow-up of a Taiwanese population-based colorectal cancer screening cohort. Lancet Oncol. 12, 551-558 (2011).
43. Haug, U., Kuntz, K. M., Knudsen, A. B., Hundt, S. & Brenner, H. Sensitivity of immunochemical faecal occult blood testing for detecting left-vs right-sided colorectal neoplasia. Br. J. Cancer 104, 1779-1785 (2011).
44. Brenner, H., Haug, U. & Hundt, S. Sex differences in performance of fecal occult blood testing. Am. J. Gastroenterol. 105, 2457-2464 (2010).
45. National Institute for Public Health and the Environment. Bowel cancer screening programme [online], http://www.rivm.nl/en/Topics/Topics/B/Bowel- cancer-screening-programme (2013).
46. Health Council of the Netherlands. A national colorectal cancer screening programme [online], http://www.gezondheidsraad.nl/sites/default/files/200913E. pdf (2009).
47. Guittet, L., Guillaume, E., Bouvier, V. & Launoy, G. Seasonal variations of immunochemical and gaiac faecal occult blood tests. Gut 60, 423-424 (2011).
48. Guittet, L. et al. Analytical comparison of three quantitative immunochemical fecal occult blood tests for colorectal cancer screening. Cancer Epidemiol. Biomarkers Prev. 20, 1492-1501 (2011).
49. van Roon, A. H. et al. Are fecal immunochemical test characteristics influenced by sample return time? A population-based colorectal cancer screening trial. Am. J. Gastroenterol. 107, 99-107 (2012).
50. Vilkin, A. et al. Performance characteristics and evaluation of an automated-developed and quantitative, immunochemical, fecal occult blood screening test. Am. J. Gastroenterol. 100, 2519-2525 (2005).
51. Grazzini, G. et al. Influence of seasonal variations in ambient temperatures on performance of immunochemical faecal occult blood test for colorectal cancer screening: observational study from the Florence district. Gut 59, 1511-1515 (2010).
52. Levin, T. R. Editorial: taking FIT to the people: out of the office and into the mail. Am. J. Gastroenterol. 107, 108-110 (2012).
53. Fraser, C. G. et al. A proposal to standardize reporting units for fecal immunochemical tests for hemoglobin. J. Natl Cancer Inst. 104, 810-814 (2012).
54. Hoff, G., Grotmol, T., Skovlund, E., Bretthauer, M. & Norwegian Colorectal Cancer Prevention Study Group. Risk of colorectal cancer seven years after flexible sigmoidoscopy screening: randomised controlled trial. BMJ 338, b1846 (2009).
55. Atkin, W. S. et al. Once-only flexible sigmoidoscopy screening in prevention of colorectal cancer: a multicentre randomised controlled trial. Lancet 375, 1624-1633 (2010).
56. Segnan, N. et al. Once-only sigmoidoscopy in colorectal cancer screening: follow-up findings of the Italian Randomized Controlled Trial-SCORE. J. Natl Cancer Inst. 103, 1310-1322 (2011).
57. Schoen, R. E. et al. Colorectal-cancer incidence and mortality with screening flexible sigmoidoscopy. N. Engl. J. Med. 366, 2345-2357 (2012).
58. Weissfeld, J. L. et al. Flexible sigmoidoscopy in the randomized prostate, lung, colorectal, and ovarian (PLCO) cancer screening trial: added yield from a second screening examination. J. Natl Cancer Inst. 104, 280-289 (2012).
59. Levin, B. et al. Screening and surveillance for the early detection of colorectal cancer and adenomatous polyps, 2008: a joint guideline from the American Cancer Society, the US MultiSociety Task Force on Colorectal Cancer, and the American College of Radiology. Gastroenterology 134, 1570-1595 (2008).
60. Lieberman, D. Colorectal cancer screening: practice guidelines. Dig. Dis. 30 (Suppl. 2), 34-38 (2012).
61. Qaseem, A. et al. Screening for colorectal cancer: a guidance statement from the American College of Physicians. Ann. Intern. Med. 156, 378-386 (2012).
62. Valori, R. et al. European guidelines for quality assurance in colorectal cancer screening and diagnosis. First edition quality assurance in endoscopy in colorectal cancer screening and diagnosis. Endoscopy 44 (Suppl. 3), SE88-SE105 (2012).
63. Hol, L. et al. Uptake of faecal immunochemical test screening among nonparticipants in a flexible sigmoidoscopy screening programme. Int. J. Cancer 130, 2096-2102 (2012).
64. Senore, C. et al. Offering people a choice for colorectal cancer screening. Gut http://dx.doi.org/10.1136/gutjnl-2011-301013.
65. Kato, J. et al. Combination of sigmoidoscopy and a fecal immunochemical test to detect proximal colon neoplasia. Clin. Gastroenterol. Hepatol. 7, 1341-1346 (2009).
66. Kaminski, M. F. et al. Quality indicators for colonoscopy and the risk of interval cancer. N. Engl. J. Med. 362, 1795-1803 (2010).
67. Stock, C., Ihle, P., Schubert, I. & Brenner, H. Colonoscopy and fecal occult blood test use in Germany: results from a large insurance-based cohort. Endoscopy 43, 771-781 (2011).
68. Winawer, S. J. et al. Prevention of colorectal cancer by colonoscopic polypectomy. The National Polyp Study Workgroup. N. Engl. J. Med. 329, 1977-1981 (1993).
69. Zauber, A. G. et al. Colonoscopic polypectomy and long-term prevention of colorectal-cancer deaths. N. Engl. J. Med. 366, 687-696 (2012).
70. Robertson, D. J. et al. Colorectal cancer in patients under close colonoscopic surveillance. Gastroenterology 129, 34-41 (2005).
71. van Rijn, J. C. et al. Polyp miss rate determined by tandem colonoscopy: a systematic review. Am. J. Gastroenterol. 101, 343-350 (2006).
72. Ramsoekh, D. et al. A back-to-back comparison of white light video endoscopy with autofluorescence endoscopy for adenoma detection in high-risk subjects. Gut 59, 785-793 (2010).
73. Pohl, H. et al. Incomplete polyp resection during colonoscopy-results of the Complete Adenoma Resection (CARE) study. Gastroenterology 144, 74-80.e1 (2012).
74. Loeve, F., van Ballegooijen, M., Boer, R., Kuipers, E. J. & Habbema, J. D. Colorectal cancer risk in adenoma patients: a nation-wide study. Int. J. Cancer 111, 147-151 (2004).
75. Baxter, N. N. et al. Association of colonoscopy and death from colorectal cancer. Ann. Intern. Med. 150, 1-8 (2009).
76. Singh, H. et al. The reduction in colorectal cancer mortality after colonoscopy varies by site of the cancer. Gastroenterology 139, 1128-1137 (2010).
77. Panteris, V., Haringsma, J. & Kuipers, E. J. Colonoscopy perforation rate, mechanisms and outcome: from diagnostic to therapeutic colonoscopy. Endoscopy 41, 941-951 (2009).
78. Kaminski, M. F. et al. The NordICC Study: rationale and design of a randomized trial on colonoscopy screening for colorectal cancer. Endoscopy 44, 695-702 (2012).
79. Rogal, S. S., Pinsky, P. F. & Schoen, R. E. Relationship between detection of adenomas by flexible sigmoidoscopy and interval distal colorectal cancer. Clin. Gastroenterol. Hepatol. 11, 73-78 (2012).
80. Bressler, B. et al. Rates of new or missed colorectal cancers after colonoscopy and their risk factors: a population-based analysis. Gastroenterology 132, 96-102 (2007).
81. Lebwohl, B. et al. The impact of suboptimal bowel preparation on adenoma miss rates and the factors associated with early repeat colonoscopy. Gastrointest. Endosc. 73, 1207-1214 (2011).
82. Armstrong, D. et al. Canadian Association of Gastroenterology consensus guidelines on safety and quality indicators in endoscopy. Can. J. Gastroenterol. 26, 17-31 (2012).
83. Jover, R. et al. Clinical practice guidelines: quality of colonoscopy in colorectal cancer screening. Endoscopy 44, 444-451 (2012).
84. Lieberman, D. A. et al. Guidelines for colonoscopy surveillance after screening and polypectomy: a consensus update by the US Multi-Society Task Force on Colorectal Cancer. Gastroenterology 143, 844-857 (2012).
85. Kim, D. H. et al. CT colonography versus colonoscopy for the detection of advanced neoplasia. N. Engl. J. Med. 357, 1403-1412 (2007).
86. Johnson, C. D. et al. Accuracy of CT colonography for detection of large adenomas and cancers. N. Engl. J. Med. 359, 1207-1217 (2008).
87. de Haan, M. C. et al. Comparing the diagnostic yields of technologists and radiologists in an invitational colorectal cancer screening program performed with CT colonography. Radiology 264, 771-778 (2012).
88. Kim, D. H., Pooler, B. D., Weiss, J. M. & Pickhardt, P. J. Five year colorectal cancer outcomes in a large negative CT colonography screening cohort. Eur. Radiol. 22, 1488-1494 (2012).
89. de Wijkerslooth, T. R. et al. Burden of colonoscopy compared to non-cathartic CT-colonography in a colorectal cancer screening programme: randomised controlled trial. Gut 61, 1552-1559 (2012).
90. Vanness, D. J. et al. Comparative economic evaluation of data from the ACRIN National CT Colonography Trial with three cancer intervention and surveillance modeling network microsimulations. Radiology 261, 487-498 (2011).
91. Liedenbaum, M. H. et al. Using CT colonography as a triage technique after a positive faecal occult blood test in colorectal cancer screening. Gut 58, 1242-1249 (2009).
92. McFarland, E. G. et al. ACR Colon Cancer Committee white paper: status of CT colonography 2009. J. Am. Coll. Radiol. 6, 756-772.e4 (2009).
93. Wilschut, J. A. et al. Fecal occult blood testing when colonoscopy capacity is limited. J. Natl Cancer Inst. 103, 1741-1751 (2011).
94. Wilschut, J. A. et al. Cost-effectiveness analysis of a quantitative immunochemical test for colorectal cancer screening. Gastroenterology 141, 1648-1655.e1 (2011).
95. Wilschut, J. A. et al. How much colonoscopy screening should be recommended to individuals with various degrees of family history of colorectal cancer? Cancer 117, 4166-4174 (2011).
96. de Wijkerslooth, T. R. et al. Adenoma detection with cap-assisted colonoscopy versus regular colonoscopy: a randomised controlled trial. Gut 61, 1426-1434 (2012).
97. Leufkens, A. M. et al. Effect of a retrograde-viewing device on adenoma detection rate during colonoscopy: the TERRACE study. Gastrointest. Endosc. 73, 480-489 (2011).
98. Leung, F. W. et al. Water-aided colonoscopy: a systematic review. Gastrointest. Endosc. 76, 657-666 (2012).
99. Adler, A. et al. Latest generation, wide-angle, high-definition colonoscopes increase adenoma detection rate. Clin. Gastroenterol. Hepatol. 10, 155-159 (2012).
100. Eliakim, R. Video capsule colonoscopy: where will we be in 2015? Gastroenterology 139, 1468-1471 (2010).
101. Spada, C. et al. Second-generation colon capsule endoscopy compared with colonoscopy. Gastrointest. Endosc. 74, 581-589 (2011).
102. Van Gossum, A. et al. Capsule endoscopy versus colonoscopy for the detection of polyps and cancer. N. Engl. J. Med. 361, 264-270 (2009).
103. Spada, C. et al. Meta-analysis shows colon capsule endoscopy is effective in detecting colorectal polyps. Clin. Gastroenterol. Hepatol. 8, 516-522 (2010).
104. Groth, S. et al. Capsule colonoscopy increases uptake of colorectal cancer screening. BMC Gastroenterol. 12, 80 (2012).
105. Osborn, N. K. & Ahlquist, D. A. Stool screening for colorectal cancer: molecular approaches. Gastroenterology 128, 192-206 (2005).
106. Bosch, L. J. et al. Molecular tests for colorectal cancer screening. Clin. Colorectal Cancer 10, 8-23 (2011).
107. Ahlquist, D. A. et al. Next-generation stool DNA test accurately detects colorectal cancer and large adenomas. Gastroenterology 142, 248-256 (2012).
108. Wild, N. et al. A combination of serum markers for the early detection of colorectal cancer. Clin. Cancer Res. 16, 6111-6121 (2010).
109. Lofton-Day, C. et al. DNA methylation biomarkers for blood-based colorectal cancer screening. Clin. Chem. 54, 414-423 (2008).
110. Tóth, K. et al. Detection of methylated SEPT9 in plasma is a reliable screening method for both left-and right-sided colon cancers. PLoS ONE 7, e46000 (2012).
111. van Roon, A. H. et al. Advance notification letters increase adherence in colorectal cancer screening: a population-based randomized trial. Prev. Med. 52, 448-451 (2011).
112. Federici, A. et al. The role of GPs in increasing compliance to colorectal cancer screening: a randomised controlled trial (Italy). Cancer Causes Control 17, 45-52 (2006).
113. von Karsa, L. et al. European guidelines for quality assurance in colorectal cancer screening and diagnosis: overview and introduction of the full supplement publication. Endoscopy 44 (Suppl. 3), SE15-SE30 (2012).
114. Yabroff, K. R. et al. Are physicians' recommendations for colorectal cancer screening guideline-consistent? J. Gen. Intern. Med. 26, 177-184 (2011).
115. van Dam, L., Kuipers, E. J., Steyerberg, E. W., van Leerdam, M. E. & de Beaufort, I. D. The price of autonomy: should we offer individuals a choice between colorectal cancer screening strategies? Lancet Oncol. 14, e38-46 (2013).
116. Segnan, N. et al. Randomized trial of different screening strategies for colorectal cancer: patient response and detection rates. J. Natl Cancer Inst. 97, 347-357 (2005).
117. Multicentre Australian Colorectal-neoplasia screening (MACS) Group. A comparison of colorectal neoplasia screening tests: a multicentre community-based study of the impact of consumer choice. Med. J. Aust. 184, 546-550 (2006).
118. Inadomi, J. M. et al. Adherence to colorectal cancer screening: a randomized clinical trial of competing strategies. Arch. Intern. Med. 172, 575-582 (2012).
119. Valori, R., Sint Nicolaas, J. & de Jonge, V. Quality assurance of endoscopy in colorectal cancer screening. Best Pract. Res. Clin. Gastroenterol. 24, 451-464 (2010).
120. Morikawa, T. et al. A comparison of the immunochemical fecal occult blood test and total colonoscopy in the asymptomatic population. Gastroenterology 129, 422-428 (2005).
121. Gavin, D. R. et al. The national colonoscopy audit: a nationwide assessment of the quality and safety of colonoscopy in the UK. Gut 62, 242-249 (2012).
122. de Jonge, V. et al. A prospective audit of patient experiences in colonoscopy using the Global Rating Scale: a cohort of 1, 187 patients. Can. J. Gastroenterol. 24, 607-613 (2010).
123. Sint Nicolaas, J. et al. The Global Rating Scale in clinical practice: a comprehensive quality assurance programme for endoscopy departments. Dig. Liver Dis. 44, 919-924 (2012).
124. Lansdorp-Vogelaar, I., van Ballegooijen, M., Zauber, A. G., Habbema, J. D. & Kuipers, E. J. Effect of rising chemotherapy costs on the cost savings of colorectal cancer screening. J. Natl Cancer Inst. 101, 1412-1422 (2009).
125. Tappenden, P. et al. Option appraisal of population-based colorectal cancer screening programmes in England. Gut 56, 677-684 (2007).
126. Holden, D. J., Jonas, D. E., Porterfield, D. S., Reuland, D. & Harris, R. Systematic review: enhancing the use and quality of colorectal cancer screening. Ann. Intern. Med. 152, 668-676 (2010).